Matches in SemOpenAlex for { <https://semopenalex.org/work/W1520139708> ?p ?o ?g. }
- W1520139708 abstract "Background and aims. Given that the pathogenesis of type 1 and 2 diabetes are markedly different, it is possible that patients with type 2 diabetes should not be treated with insulin following the principles used for treatment of type 1 diabetes. The present studies were undertaken to define 1) the optimal insulin treatment regimen for type 2 diabetic patients with secondary failure to oral anti-diabetic drugs (OAD), 2) causes of inter-individual variation in insulin requirements in type 2 diabetic patients and 3) how improvement of glycemic control by insulin therapy influences markers of endothelial activation as measured by serum concentrations of the soluble adhesion molecules sE-selectin and vascular cell adhesion molecule (sVCAM-1). Subjects, study designs and methods. 153 poorly controlled type 2 diabetic patients who were treated with maximal doses of sulfonylurea alone or in combination with metformin were randomized to treatment for 3 months with either continued OAD and NPH insulin in the evening or continued OAD and NPH insulin in the morning, a 2 insulin injection regimen without OAD or a multiple insulin injection regimen without OAD. The goal was to achieve similar glycemic control with all insulin regimens and to compare effects of various regimens on insulin requirements, body weight, serum lipids and lipoproteins and episodes of hypoglycemia (study I). Study II was designed to determine what bedtime NPH insulin should be combined with, a sulfonylurea, metformin, both drugs or another injection of NPH insulin. Ninety-six type 2 diabetic patients who were treated with a maximal dose of sulfonylurea, were randomized to treatment for one year with bedtime NPH insulin and glibenclamide, or bedtime NPH insulin and metformin, or bedtime NPH insulin and glibenclamide and metformin, or bedtime NPH insulin and morning NPH insulin. The patients were taught to self adjust their insulin doses. In study III, 20 type 2 diabetic patients with stable glucose control and insulin dose, who were treated with combination therapy with bedtime NPH insulin and metformin for at least 1 year were studied. In each subject, the following measurements were performed: 1) measurement of action of intravenous insulin on endogenous glucose production (EGO) and utilization, (euglycemic insulin clamp combined with [3-H]glucose) 2) measurement of absorption (increase in free insulin and total insulin over 8 h after subcutaneous dose of regular insulin) and action of subcutaneous insulin (glucose infusion rate required to maintain euglycemia and suppress FFA) and 3) measurement of liver (proton spectroscopy) and intra-abdominal (magnetic resonance imaging) fat content and in addition, body weight, body composition, and the thickness of subcutaneous abdominal (ultrasound) fat were determined. In study IV, 81 type 2 diabetic patients, who participated in study II and 41 normal subjects were studied. In these groups, concentrations of serum sE-selectin and sVCAM-1 concentrations were determined. In the type 2 diabetic patients, the measurements were repeated at 3 and 12 months. Results. Study I: The mean insulin doses of NPH insulin in the two groups receiving an OAD and NPH insulin were similar and 60 % lower than in the 2-injection or multiple injection group. The total doses of insulin were comparable in the 2and multiple insulin injection groups. HbA1c concentrations decreased from approximately 8 to 10 % in all the insulintreatment groups. All groups receiving insulin therapy gained weight. The smallest increment in body weight occurred in the OAD and evening NPH insulin group and the largest in the multiple-injection group (p < 0.05). The frequency of hypoglycemia was similar in all insulin treated groups. The concentration of serum VLDL triglycerides decreased by 13 to 28 % in the insulin treatment groups with no differences between the groups who used insulin. The concentrations of total, LDL, and HDL cholesterol remained unchanged. Study II: Patients receiving bedtime insulin and metformin showed a progressive decrease in HbA1c concentrations over time. At 12 months, HbA1c values in this group averaged 7.2 % ± 0,2 %; which differed significantly from that in the other groups. Patients receiving bedtime insulin and metformin did not gain weight unlike the other groups. The frequency of hypoglycemic episodes in patients receiving bedtime insulin and metformin was significantly lower (p < 0.05) than that in patients receiving bedtime and morning insulin. Hypoglycemia limited adequate titration of the insulin dose in the group using NPH insulin and glibenclamide. Serum triglyceride concentrations decreased similarly in all groups. Study III: The amount of insulin absorbed was significantly correlated with glucose infusion rate required to maintain euglycemia ( r = 0.74, p < 0.001) and suppression of FFA ( r = -0.63, p < 0.005). On the other hand, the actions of intravenous and subcutaneous insulin were so closely correlated that the contribution of variation in insulin absorption to interindividual variation in insulin action was maximally 30 %. Of the relationships of measures of overall adiposity and fat distribution, the % liver fat was the best correlate of the % suppression of EGO by intravenous insulin. In multiple linear regression, 61.3% of variation in the daily insulin dose (units per day) could be explained by variation in the ability of subcutaneous insulin to suppress FFA (p < 0.001) and by insulin antibodies (p = 0.05). Of all measures of adiposity, the % liver fat was the parameter best correlated with the insulin dose. Study IV. Serum sE-selectin concentrations were 71 % higher in the type 2 diabetic patients than in the normal subjects before insulin therapy. During insulin therapy, sE-selectin concentrations decreased significantly compared to 0 month but the concentration at 12 months was still 55 % higher than in the normal subjects. Serum sVCAM-1 decreased transiently during the first 3 months and then increased back to baseline by 12 months. The change in HbA1c, both in diabetic men and women, was significantly correlated with the change in sE-selectin concentrations. Conclusions. In poorly controlled type 2 diabetic patients receiving OAD therapy, the addition of NPH insulin in the evening improves glycemic control in a similar manner as a two-insulin-injection therapy regimen and multiple-insulin-therapy regimen, but induces less weight gain and hyperinsulinemia. Combination therapy with bedtime insulin and metformin prevents weight gain and seems superior to other bedtime insulin regimens with respect to improvement in glycemic control and frequency of hypoglycemia. Self-adjustment of the insulin dose is critically important to achieve glycemic targets. The major reason for interindividual variation in insulin requirements in type 2 diabetes is variation in insulin action. Variation in hepatic fat content may influence insulin requirements via an effect on the sensitivity of EGO to insulin. Improvement in glycemic control by insulin alone or insulin combined with either glibenclamide, metformin, or both agents induces a sustained decrease in sE-selectin, the magnitude of which seems to be dependent on the degree of improvement in glycemic control. Serum sE-selectin might provide a marker of effects of treatment of chronic hyperglycemia on endothelial activation." @default.
- W1520139708 created "2016-06-24" @default.
- W1520139708 creator A5036744785 @default.
- W1520139708 date "2001-12-01" @default.
- W1520139708 modified "2023-09-23" @default.
- W1520139708 title "Insulin Treatment in Type 2 Diabetes" @default.
- W1520139708 cites W1023315294 @default.
- W1520139708 cites W105501348 @default.
- W1520139708 cites W144537546 @default.
- W1520139708 cites W1484535674 @default.
- W1520139708 cites W1519050139 @default.
- W1520139708 cites W15365198 @default.
- W1520139708 cites W1593658146 @default.
- W1520139708 cites W1593789026 @default.
- W1520139708 cites W1695602471 @default.
- W1520139708 cites W170203718 @default.
- W1520139708 cites W173889134 @default.
- W1520139708 cites W1857052429 @default.
- W1520139708 cites W1905676878 @default.
- W1520139708 cites W1913023909 @default.
- W1520139708 cites W1917931603 @default.
- W1520139708 cites W1922274789 @default.
- W1520139708 cites W192310773 @default.
- W1520139708 cites W1951442280 @default.
- W1520139708 cites W1964227153 @default.
- W1520139708 cites W1964592662 @default.
- W1520139708 cites W1965100093 @default.
- W1520139708 cites W1965695614 @default.
- W1520139708 cites W1966158190 @default.
- W1520139708 cites W1966932663 @default.
- W1520139708 cites W1967943195 @default.
- W1520139708 cites W1968319423 @default.
- W1520139708 cites W1968982269 @default.
- W1520139708 cites W1969550954 @default.
- W1520139708 cites W1970337257 @default.
- W1520139708 cites W1971128106 @default.
- W1520139708 cites W1971493468 @default.
- W1520139708 cites W1971735908 @default.
- W1520139708 cites W1971781956 @default.
- W1520139708 cites W1971868117 @default.
- W1520139708 cites W1972182005 @default.
- W1520139708 cites W1972460411 @default.
- W1520139708 cites W1974127796 @default.
- W1520139708 cites W1974273507 @default.
- W1520139708 cites W1974320211 @default.
- W1520139708 cites W1974657065 @default.
- W1520139708 cites W1975136502 @default.
- W1520139708 cites W1975856506 @default.
- W1520139708 cites W1976442813 @default.
- W1520139708 cites W1976746636 @default.
- W1520139708 cites W1976778785 @default.
- W1520139708 cites W1977164489 @default.
- W1520139708 cites W1977797609 @default.
- W1520139708 cites W1978027514 @default.
- W1520139708 cites W1978734462 @default.
- W1520139708 cites W1979110885 @default.
- W1520139708 cites W1979286266 @default.
- W1520139708 cites W1979402100 @default.
- W1520139708 cites W1980271476 @default.
- W1520139708 cites W1980625121 @default.
- W1520139708 cites W1981056991 @default.
- W1520139708 cites W1981456793 @default.
- W1520139708 cites W1982313710 @default.
- W1520139708 cites W1983338308 @default.
- W1520139708 cites W1984033419 @default.
- W1520139708 cites W1985317064 @default.
- W1520139708 cites W1986314541 @default.
- W1520139708 cites W1986349550 @default.
- W1520139708 cites W1986686287 @default.
- W1520139708 cites W1986871966 @default.
- W1520139708 cites W1986955391 @default.
- W1520139708 cites W1987371339 @default.
- W1520139708 cites W1987505479 @default.
- W1520139708 cites W1988078426 @default.
- W1520139708 cites W1988392674 @default.
- W1520139708 cites W1989021183 @default.
- W1520139708 cites W1989440602 @default.
- W1520139708 cites W1990593445 @default.
- W1520139708 cites W1990905803 @default.
- W1520139708 cites W1991136224 @default.
- W1520139708 cites W1991255033 @default.
- W1520139708 cites W1991403690 @default.
- W1520139708 cites W1991925603 @default.
- W1520139708 cites W1992066172 @default.
- W1520139708 cites W1992838000 @default.
- W1520139708 cites W1993034883 @default.
- W1520139708 cites W1993294205 @default.
- W1520139708 cites W1994999237 @default.
- W1520139708 cites W1996083033 @default.
- W1520139708 cites W1996810831 @default.
- W1520139708 cites W1997531824 @default.
- W1520139708 cites W1998714276 @default.
- W1520139708 cites W2000724007 @default.
- W1520139708 cites W2001463662 @default.
- W1520139708 cites W2001978965 @default.
- W1520139708 cites W2001979704 @default.
- W1520139708 cites W2002356255 @default.
- W1520139708 cites W2002565780 @default.
- W1520139708 cites W2002833122 @default.
- W1520139708 cites W2003301702 @default.